Skip to main content
. 2015 May 22;10(5):e0128159. doi: 10.1371/journal.pone.0128159

Fig 2. EGFR is a compensatory, not concomitant survival pathway in c-Met+ HCC.

Fig 2

A) Immunoblot of c-Met- cell lines Huh7 and Hep3B and c-Met+ cell lines MHCC97-L and MHCC97-H 24 hours post EGF treatment (0, 50, or 100 ng/ml) for EGFR, Akt and Erk signaling pathway activation. B) XTT cell viability assay of c-Met-cell line Huh7 treated with c-Met inhibitor PHA665752 (1 μM), EGFR inhibitor gefitinib (10 μM) or DMSO control 48 hours after treatment. C) XTT cell viability assay of c-Met+ MHCC97-H treated with c-Met inhibitor PHA665752 (1 μM), EGFR inhibitor gefitinib (10 μM) or DMSO control 48 hours after treatment. D) XTT cell viability assay of c-Met+ SNU-449 cell line treated with c-Met inhibitor PHA665752 (5 μM), EGFR inhibitor gefitinib (10 μM) or DMSO control for 48 hours. *statistically significant compared to DMSO control by Student t-test (p <0.05).